Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADVAX: Pembrolizumab + Radiation in Urothelial Cancer
NCT02880345Phase 1Withdrawn
- Sponsor
- Abramson Cancer Center
- Start
- Aug 2016
- Primary completion
- Aug 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in urothelial carcinoma (UC) (2 cohorts), sponsored by Abramson Cancer Center. Primary endpoint: Number of Adverse Events at 2 years. Planned start Aug 2016; status: withdrawn.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02880345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02880345.